Diagnostic value of serum HE4 combined with CA125 for benign and malignant gynecologic tumors

Abstract

Objective To investigate the diagnostic value of serum human epididymis protein 4 (HE4) combined with carbohydrate antigen (CA125) for gynecologic benign and malignant tumors, which provides a new direction for clinical diagnosis of gynecologic benign and malignant tumors. Methods A total of 128 gynecologic tumor patients treated in Jiyuan People’s Hospital from January 2016 to January 2017 were selected as experimental group, and were divided into benign tumor group (hysteromyoma group) and malignant tumor group (endometrial cancer group, cervical cancer group and ovarian cancer group) according to tumor nature. Another 60 healthy persons were selected as control group. The levels of serum HE4 and CA125 were observed and compared among groups, and their diagnostic value of combination of them for malignant gynecologic tumor was analyzed. Results There was no significant difference in HE4 level and CA125 level between control group and hysteromyoma group (P>0.05). There was a significant difference in HE4 level and CA125 level between control group and endometrial cancer group, cervical cancer group and ovarian cancer group (P 0.5. Conclusions Serum HE4 combined with CA125 is effective in the diagnosis of benign and malignant gynecologic tumors. It has the accuracy in diagnosis and is worthy of clinical promotion. Key words: Human epididymis protein 4; Carbohydrate antigen; Gynecological benign and malignant tumor; Diagnostic effect